Gujarat Themis Biosyn Ltd approves Q2 FY27 results, reporting ₹49.92 crore consolidated revenue and ₹13.84 crore net loss
- Consolidated revenue rose 17.9% year on year; results include MicroBiopharm Japan from September 18 and are not directly comparable with prior periods.
- Consolidated loss included a ₹1.17 crore exceptional charge linked to an earthquake at a step-down subsidiary.
- Standalone revenue increased 12.1% year on year to ₹47.46 crore, while net profit fell 40.6% to ₹8.47 crore.
- Auditors issued unmodified limited-review conclusions; Company Secretary Vineet Gawankar resigns effective November 30, 2026.
